02nd March 2022 | Pharma Updates
Panacea Biotec Wins CDSCO Approval for Pentavalent Vaccine
The drugmaker will market pentavalent vaccine for 5 diseases Tetanus, Pertussis, Haemophilus, Poliomyelitis and Diphtheria.
Mankind Pharma to purchase Panacea’s formulations brands for Rs. 1872 cr
Definitive agreements have been inked between both companies and the transaction is likely to be completed by this month.
Delpharm Buys Sandoz Sterile Injectable Production Plant
The plant is the largest sterile injectables production facility in Canada and provides drugs to the Canadian and USA healthcare systems.
Amneal Gets Approval to Market Releuko
Releuko is used to treat chemotherapy patients suffering from neutropenia.
TruPharma Brings First Generic Version of APOKYN® Cartridges
The drugmaker has started commercial marketing of Sage’s FDA-cleared generic cartridge product.
LGMD Gene Therapy ATA-100 Receives Orphan Drug Status
The FDA has given orphan drug designation to Atamyo Therapeutics’s ATA-100 for a specific form of limbgirdle muscular dystrophy (LGMD) called 2I or R9 (LGMD2I/R9).
AbbVie Purchases Syndesi for USD 130 MN Upfront
AbbVie has expanded its neuroscience portfolio with novel modulators of the synaptic vesicle protein 2A, including Syndesi’s lead molecule SDI-118.
Novartis Ringaskiddy to be sold to Sterling Pharma Solutions
According to the agreement, Sterling Pharma Solutions will make drugs in Ireland for Novartis.
FDA Okays Pacritinib for Patients with Myelofibrosis
Myelofibrosis is a rare blood cancer that leads to impaired production of normal blood cells.
USFDA Clears Janssen Pharma’s Carvykti
The US’s drug regulator has approved Janssen Pharmaceutical’s first cell therapy Carvykti to treat relapsed or refractory multiple myeloma in adult patients.